ELI LILLY & Co (LLY) operating KPIs
LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1417.54+43.84 (+3.19%)
Close on Oct 30, 2026Market cap $1.33TP/E 46.0Yield 0.44%
Eli Lilly diabetes — U.S. revenue ($M) [legacy] ($M)
Annual figures from Eli Lilly's filings and investor materials
Latest, FY2022
9,911
Period ended Dec 31, 2022
Change on a year earlier
+13.7%
8,719 in FY2021
History
5 years
Since FY2018
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Diabetes — U.S. revenue ($M) [legacy] ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 9,911 | +13.7% | Form 10-K (filed 2023-02-22) ↗ |
| FY2021 | Dec 31, 2021 | 8,719 | +10.2% | Form 10-K (filed 2023-02-22) ↗ |
| FY2020 | Dec 31, 2020 | 7,909 | +5.0% | Form 10-K (filed 2023-02-22) ↗ |
| FY2019 | Dec 31, 2019 | 7,530 | +14.0% | Form 10-K (filed 2022-02-23) ↗ |
| FY2018 | Dec 31, 2018 | 6,607 | – | Form 10-K (filed 2021-02-17) ↗ |
Cite this data
StockData. (2026). Eli Lilly Diabetes — U.S. revenue ($M) [legacy] ($M), annual FY2018–FY2022 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/ta_diabetes_us_legacy
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.